↓ Skip to main content

Dove Medical Press

Article Metrics

Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
29 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
58 Mendeley
Title
Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis
Published in
International Journal of Chronic Obstructive Pulmonary Disease, August 2017
DOI 10.2147/copd.s140603
Pubmed ID
Authors

Zheng Zeng, Dan Yang, Xiaoling Huang, Zhenliang Xiao

Abstract

COPD is the fourth leading cause of death in the world. It is a common, progressive, treatable and preventable disease. The exacerbation of COPD is associated with the peripheral muscle force, forced expiratory volume in 1 second (FEV1), the quality of life and mortality. Many studies indicated that the mucoactive medicines could reduce the exacerbations of COPD. This study summarized the efficacy of carbocisteine as a treatment for COPD. We searched the randomized controlled trials (RCTs) following electronic bibliographic databases: MedLine, Embase, Cochrane Library and Web of Science. We additionally searched gray literature database: OpenSIGLE. We also additionally searched the clinical trial registers: ClinicalTrials.gov register and International Clinical Trials Registry Platform Search Portal. We used RCTs to assess the efficacy of the treatments. We included studies of adults (older than 18 years) with COPD. We excluded studies that were published as protocol or written in non-English language (Number 42016047078). Our findings included data from four studies involving 1,357 patients. There was a decrease in the risk of the rate of total number of exacerbations with carbocisteine compared with placebo (-0.43; 95% confidence interval [CI] -0.57, -0.29, P<0.01). Carbocisteine could also improve the quality of life (-6.29; 95% CI -9.30, -3.27) and reduce the number of patients with at least one exacerbation (0.86; 95% CI 0.78, 0.95) compared with placebo. There was no significant difference in the FEV1 and adverse effects and the rate of hospitalization. Long-term use of carbocisteine (500 mg TID) may be associated with lower exacerbation rates, the smaller number of patients with at least one exacerbation and higher quality of life of patients with COPD.

Twitter Demographics

The data shown below were collected from the profiles of 29 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 58 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 16%
Student > Bachelor 9 16%
Researcher 5 9%
Student > Doctoral Student 4 7%
Lecturer 4 7%
Other 12 21%
Unknown 15 26%
Readers by discipline Count As %
Medicine and Dentistry 20 34%
Pharmacology, Toxicology and Pharmaceutical Science 12 21%
Nursing and Health Professions 4 7%
Biochemistry, Genetics and Molecular Biology 2 3%
Agricultural and Biological Sciences 1 2%
Other 3 5%
Unknown 16 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2022.
All research outputs
#2,001,482
of 22,320,492 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#189
of 2,315 outputs
Outputs of similar age
#38,911
of 291,936 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#8
of 58 outputs
Altmetric has tracked 22,320,492 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,315 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,936 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.